Mediwound Ltd
MDWD17.950USD
+0.160+0.90%
收盘 02/09, 16:00（美东）报价延迟15分钟
40.22M总市值
亏损市盈率 TTM
关于 Mediwound Ltd 公司
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Mediwound Ltd简介
公司代码MDWD
公司名称Mediwound Ltd
上市日期Mar 20, 2014
CEOGonen (Ofer)
员工数量111
证券类型Ordinary Share
年结日Mar 20
公司地址42 Hayarkon Street
城市YAVNE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Israel
邮编8122745
电话972779714100
网址https://www.mediwound.com/
公司代码MDWD
上市日期Mar 20, 2014
CEOGonen (Ofer)
Mediwound Ltd公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Ofer Gonen
Mr. Ofer Gonen
Chief Executive Officer, Director
Chief Executive Officer, Director
182.10K
+83371.00%
Dr. Vickie R. Driver, M.D.
Dr. Vickie R. Driver, M.D.
Independent Director
Independent Director
--
--
Mr. Stephen T. Wills, CPA
Mr. Stephen T. Wills, CPA
Independent Director
Independent Director
--
--
Dr. Ety Klinger, Ph.D.
Dr. Ety Klinger, Ph.D.
Chief Research and Development Officer
Chief Research and Development Officer
--
--
Mr. Yaron Meyer
Mr. Yaron Meyer
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
--
--
Mr. David Fox
Mr. David Fox
Independent Director
Independent Director
--
--
Mr. Jeremy Feffer
Mr. Jeremy Feffer
Managing Director
Managing Director
--
--
Mr. Shmuel (Milky) Rubinstein
Mr. Shmuel (Milky) Rubinstein
Independent Director
Independent Director
--
--
Dr. Shmulik Hess
Dr. Shmulik Hess
Chief Operating Officer, Chief Commercial Officer
Chief Operating Officer, Chief Commercial Officer
--
--
Ms. Hani Luxenburg
Ms. Hani Luxenburg
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Ofer Gonen
Mr. Ofer Gonen
Chief Executive Officer, Director
Chief Executive Officer, Director
182.10K
+83371.00%
Dr. Vickie R. Driver, M.D.
Dr. Vickie R. Driver, M.D.
Independent Director
Independent Director
--
--
Mr. Stephen T. Wills, CPA
Mr. Stephen T. Wills, CPA
Independent Director
Independent Director
--
--
Dr. Ety Klinger, Ph.D.
Dr. Ety Klinger, Ph.D.
Chief Research and Development Officer
Chief Research and Development Officer
--
--
Mr. Yaron Meyer
Mr. Yaron Meyer
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
--
--
Mr. David Fox
Mr. David Fox
Independent Director
Independent Director
--
--
收入明细
单位: USD更新时间: 1月6日 周二
单位: USD更新时间: 1月6日 周二
FY2024
FY2023
FY2022
FY2021
FY2020
由于公司未披露，未能获取相关数据
地区USD
名称
营收
占比
USA
15.46M
76.47%
EU and other international markets
4.76M
23.53%
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 1月31日 周六
更新时间: 1月31日 周六
持股股东
股东类型
持股股东
持股股东
占比
Clal Biotechnology Industries Ltd
11.54%
Investor AB
6.79%
Yelin Lapidot Provident Funds Management Ltd
5.95%
Rosalind Advisors, Inc.
5.84%
HOLD Alapkezelo Zrt
5.48%
其他
64.40%
持股股东
持股股东
占比
Clal Biotechnology Industries Ltd
11.54%
Investor AB
6.79%
Yelin Lapidot Provident Funds Management Ltd
5.95%
Rosalind Advisors, Inc.
5.84%
HOLD Alapkezelo Zrt
5.48%
其他
64.40%
股东类型
持股股东
占比
Investment Advisor
22.88%
Holding Company
11.54%
Hedge Fund
10.80%
Investment Advisor/Hedge Fund
8.43%
Private Equity
6.79%
Venture Capital
2.95%
Corporation
2.17%
Individual Investor
1.42%
Research Firm
0.83%
其他
32.19%
机构持股
更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
148
6.94M
54.04%
+1.56M
2025Q3
135
5.72M
44.57%
+391.20K
2025Q2
127
6.70M
61.97%
-1.10M
2025Q1
129
6.76M
62.72%
-1.01M
2024Q4
118
7.26M
67.33%
+161.02K
2024Q3
115
7.34M
70.49%
+440.76K
2024Q2
91
5.75M
66.40%
+288.97K
2024Q1
69
5.35M
61.63%
-376.56K
2023Q4
61
5.55M
64.63%
+32.10K
2023Q3
62
5.26M
71.22%
+1.01M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Clal Biotechnology Industries Ltd
1.48M
11.55%
--
--
Sep 30, 2025
Investor AB
872.09K
6.8%
--
--
Sep 30, 2025
Yelin Lapidot Provident Funds Management Ltd
809.95K
6.32%
-6.79K
-0.83%
Sep 30, 2025
Rosalind Advisors, Inc.
749.05K
5.84%
+341.99K
+84.02%
Sep 30, 2025
HOLD Alapkezelo Zrt
703.43K
5.49%
+703.43K
--
Sep 22, 2025
T. Rowe Price Associates, Inc.
599.38K
4.67%
+230.30K
+62.40%
Sep 30, 2025
Israel Biotech Fund
378.62K
2.95%
-172.63K
-31.32%
Mar 15, 2025
BlackRock Institutional Trust Company, N.A.
363.39K
2.83%
-24.88K
-6.41%
Sep 30, 2025
Meitav Investment House Ltd
291.62K
2.27%
+260.12K
+825.71%
Sep 30, 2025
Deep Insight Limited Partnership
278.18K
2.17%
-273.07K
-49.54%
Mar 15, 2025
查看更多
持股ETF
更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
ARK Israel Innovative Technology ETF
1.64%
Invesco NASDAQ Future Gen 200 ETF
0.59%
iShares Micro-Cap ETF
0.03%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
ARK Israel Innovative Technology ETF
占比1.64%
Invesco NASDAQ Future Gen 200 ETF
占比0.59%
iShares Micro-Cap ETF
占比0.03%
iShares Russell 2000 Growth ETF
占比0.01%
Global X Russell 2000 ETF
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
iShares Russell 2000 ETF
占比0%
Proshares Ultra Russell 2000
占比0%
ProShares UltraPro Russell2000
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
公告日期
除权除息日
类型
比率
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
